Improvement of refractory cognitive impairment following anifrolumab treatment in a patient with systemic lupus erythematosus

Anifrolumab, a monoclonal antibody targeting the type I interferon receptor, has been approved for the treatment of systemic lupus erythematosus (SLE). However, its role in cognitive impairment remains unclear. A woman in her early 70s was diagnosed with SLE based on the presence of pancytopenia, proteinuria, hypocomplementemia, and elevated serum anti-double-stranded DNA antibody levels. Treatment was initiated with oral prednisolone at 50 mg/day and intravenous cyclophosphamide at 500 mg. Cognitive dysfunction persisted despite improvements in systemic manifestations, with a decreased Mini-Mental State Examination (MMSE) score and abnormalities on the clock drawing test (CDT). Results from brain magnetic resonance imaging were unremarkable. Cerebrospinal fluid analysis showed mildly elevated interleukin-6 levels, but negative results for anti-ribosomal P antibodies. Although delirium was initially considered among the differential diagnoses, the patient did not meet the criteria for delirium. Cognitive impairment associated with SLE disease activity was therefore suspected. A second infusion of cyclophosphamide was administered, but cognitive impairment exacerbated. Intravenous infusion of anifrolumab was subsequently initiated, after which cognitive function improved over several days, with increasing MMSE score and normalization of CDT performance. No relapse of SLE was seen with anifrolumab every four weeks combined with hydroxychloroquine, and prednisolone was tapered to 4 mg/day by 11 months after treatment initiation. Although the relative contributions of neuropsychiatric involvement and excessive type I interferon activity to cognitive impairment remain uncertain, this case raises the possibility that anifrolumab may have contributed to the improvement of cognitive impairment.

Authors

Institutions

Publication Details

Journal
Modern Rheumatology Case Reports
Published
2026-11-21
DOI
https://doi.org/10.1093/mrcr/rxag115
Primary Topic
Systemic Lupus Erythematosus Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Improvement of refractory cognitive impairment following anifrolumab treatment in a patient with systemic lupus erythematosus

Shunichiro Hanai, Daiki Nakagomi, Mayu Yazaki, Nakako Tanaka‐Mabuchi et al.
Modern Rheumatology Case Reports
Systemic Lupus Erythematosus Research
article

Improvement of refractory cognitive impairment following anifrolumab treatment in a patient with systemic lupus erythematosus

Shunichiro Hanai, Daiki Nakagomi, Mayu Yazaki, Nakako Tanaka‐Mabuchi, Sunao Kubota, Kojiro Ikeda
article en

Abstract

Anifrolumab, a monoclonal antibody targeting the type I interferon receptor, has been approved for the treatment of systemic lupus erythematosus (SLE). However, its role in cognitive impairment remains unclear. A woman in her early 70s was diagnosed with SLE based on the presence of pancytopenia, proteinuria, hypocomplementemia, and elevated serum anti-double-stranded DNA antibody levels. Treatment was initiated with oral prednisolone at 50 mg/day and intravenous cyclophosphamide at 500 mg. Cognitive dysfunction persisted despite improvements in systemic manifestations, with a decreased Mini-Mental State Examination (MMSE) score and abnormalities on the clock drawing test (CDT). Results from brain magnetic resonance imaging were unremarkable. Cerebrospinal fluid analysis showed mildly elevated interleukin-6 levels, but negative results for anti-ribosomal P antibodies. Although delirium was initially considered among the differential diagnoses, the patient did not meet the criteria for delirium. Cognitive impairment associated with SLE disease activity was therefore suspected. A second infusion of cyclophosphamide was administered, but cognitive impairment exacerbated. Intravenous infusion of anifrolumab was subsequently initiated, after which cognitive function improved over several days, with increasing MMSE score and normalization of CDT performance. No relapse of SLE was seen with anifrolumab every four weeks combined with hydroxychloroquine, and prednisolone was tapered to 4 mg/day by 11 months after treatment initiation. Although the relative contributions of neuropsychiatric involvement and excessive type I interferon activity to cognitive impairment remain uncertain, this case raises the possibility that anifrolumab may have contributed to the improvement of cognitive impairment.

Modern Rheumatology Case Reports
University of Yamanashi Hospital (JP), University of Yamanashi (JP)
Systemic Lupus Erythematosus Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon